The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 350
- 试验地点
- 6
- 主要终点
- Percentage of patients where the site of origin is identified
研究概览
简要总结
The goal of this clinical trial is to improve diagnosis and treatment strategies for patients with Cancer of Unknown Primary (CUP) by using advanced molecular profiling to identify the likely tumor origin and guide therapy.
The main questions it aims to answer are:
Can comprehensive molecular profiling help determine the origin of CUP tumors? Does identifying the tumor origin improve treatment choices and survival outcomes compared to historical data?
Participants will:
- Undergo a new biopsy to collect tumor tissue for advanced analyses.
- Provide blood samples for circulating tumor DNA (cfDNA/ctDNA) analyses.
- Provide a fecal sample for microbiome analysis.
- Have their tumor tissue analyzed using:
Methylation profiling and comprehensive gene panel testing.
- Have the results reviewed in a specialized CUP molecular MDT meeting to determine the likely tumor origin and guide treatment.
- Have their tumor tissue samples biobanked for further exploratory whole genome sequencing (WGS) and RNA sequencing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ECOG PS 0-
- •Life expectancy minimum 3 months.
- •Radiologically verified metastatic disease (CT thorax/abdomen/pelvis) with no radiological signs of primary tumor.
- •Histologically verified metastatic disease of unknown primary. Morphological and immunohistochemical findings suggesting a possible, but not definitive, origo is eligible.
- •Eligible histologies include adenocarcinoma, squamous cell carcinoma, poorly and undifferentiated carcinoma and undifferentiated neoplasms.
- •Clinically relevant endoscopic examinations have been performed as indicated by clinical, radiological and pathological findings, without identification of a primary tumor.
- •Clinically relevant supplementary radiological examinations have been performed as indicated by clinical, radiological and pathological findings, with no radiological signs of primary tumor (e.g. PET/CT, mammography/MR mammae).
- •Metastatic lesion available for biopsy. Protocol deviation may be allowed if lesion is not technically available for biopsy. For patients with metastatic lesion technically available for biopsy, the patient must be deemed medically fit to undergo a metastatic biopsy, as assessed by the investigator.
- •Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
排除标准
- •Patients with any clinically significant medical or psychiatric condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.
- •Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.
研究组 & 干预措施
Comprehensive molecular profiling
Tumor methylation analyses, cfDNA methylation analyses, Whole Genome Sequencing, RNA sequencing, Broad targeted NGS panel analyses
干预措施: Comprehensive molecular profiling (Genetic)
结局指标
主要结局
Percentage of patients where the site of origin is identified
时间窗: From enrollment to the conclusion at the CUP molecular MDT at 8 weeks
Site of origin identified is defined as the cases where the CUP molecular MDT concludes with a likely primary site of origin
Percentage of patients where treatment choice differs from empirical CUP regimen
时间窗: From conclusion at the CUP molecular MDT to the start of subsequent treatment within a timeframe of 36 months from study inclusion
Organ specific treatment chosen over empirical CUP treatment, based on the conclusion from the CUP MDT
次要结局
- Progression free survival(From the date of first administration of a treatment line to the date of progression or death, or censored if alive at time of analysis, with a timeframe of 36 months from study inclusion.)
- Overall survival(From date of CUP diagnosis until death from any cause or censored if alive at date of analysis, within a timeframe of 36 months from study inclusion.)
- Identification of tumor site using molecular profiling methods(From study enrollment to the conclusion at the CUP molecular MDT at 8 weeks)
- Incidence of molecular alterations and use of targeted treatment in CUP patients(From molecular profiling to initiation of targeted therapy and follow-up for survival outcomes, within a timeframe of 36 months from study inclusion.)
- Impact of CUP molecular MDT assessement on previous clinical work-up(From enrollment until CUP mol MDT at 8 weeks)